{"id":"ad-2281","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Diarrhea"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AD-2281 works by inhibiting the PI3K/AKT pathway, which is involved in cell proliferation and survival. This inhibition leads to the reduction of tumor growth and metastasis. The exact molecular mechanism of AD-2281 is still being researched.","oneSentence":"AD-2281 is a small molecule that targets the PI3K/AKT pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:26.837Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT06858865","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2025-07-12","conditions":"Primary Hypercholesterolaemia","enrollment":60},{"nctId":"NCT06747936","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282","status":"NOT_YET_RECRUITING","sponsor":"Addpharma Inc.","startDate":"2025-02","conditions":"Primary Hypercholesterolemia","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AD-2281","genericName":"AD-2281","companyName":"Addpharma Inc.","companyId":"addpharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AD-2281 is a small molecule that targets the PI3K/AKT pathway. Used for Metastatic breast cancer, Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}